Zydus Lifesciences Performance
52 Week Range
- Open Price
- Previous Close
Start SIP in Zydus LifesciencesStart SIP
Zydus Lifesciences Investment Rating
Zydus Lifesciences has an operating revenue of Rs. 17,580.30 Cr. on a trailing 12-month basis. An annual revenue growth of 12% is good, Pre-tax margin of 15% is great, ROE of 11% is good. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading close to its 50DMA and comfortably placed above its 200DMA, around 17% above 200DMA. It needs to take support around the 50 DMA level to continue further upside move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 57 which is a POOR score indicating inconsistency in earnings, a RS Rating of 74 which is FAIR indicating the recent price performance, Buyer Demand at B+ which is evident from recent demand for the stock, Group Rank of 95 indicates it belongs to a poor industry group of Medical-Generic Drugs and a Master Score of C is fair but needs to improve. Overall, the stock has mediocre technical strength and poor fundamentals, there are superior stocks in the current market environment.
|Indicator||Mar 2023||Dec 2022||Sep 2022||Jun 2022||Mar 2022|
|Oper Rev Qtr Cr||2,437||2,087||2,217||1,981||1,919|
|Operating Expenses Qtr Cr||1,807||1,628||1,720||1,437||1,562|
|Operating Profit Qtr Cr||773||459||679||544||458|
|Depreciation Qtr Cr||120||122||124||123||123|
|Interest Qtr Cr||85||89||64||41||42|
|Tax Qtr Cr||124||129||149||101||100|
|Net Profit Qtr Cr||491||256||451||332||247|
Zydus Lifesciences Technicals
EMA & SMA
- Bullish Moving Average
- Bearish Moving Average
- 20 Day
- 50 Day
- 100 Day
- 200 Day
- 20 Day
- 50 Day
- 100 Day
- 200 Day
Zydus Lifesciences Resistance and Support
|MACD Single Line||0.74|
Zydus Lifesciences Delivery and Volume
|Period||NSE + BSE Volume Avg||NSE + BSE Delivery Volume Avg||NSE + BSE Delivery Volume %|
Zydus Lifesciences Result Highlights
Zydus Lifesciences Synopsis
NSE-Medical-Generic DrugsZydus Lifesciences is involved in the business activities of Manufacture of medicinal substances used in the manufacture of pharmaceuticals: antibiotics, endocrine products, basic vitamins; opium derivatives; sulpha drugs; serums and plasmas; salicylic acid, its salts and esters; glycosides and vegetable alkaloids; chemically pure suger etc.. Company’s Total Operating Revenue is Rs. 8731.60 Cr. and Equity Capital is Rs. 101.20 Cr. for the Year ended 31/03/2023. Zydus Lifesciences Ltd. is a Public Limited Listed company incorporated on 15/05/1995 and has its registered office in the State of Gujarat, India. Company’s Corporate Identification Number(CIN) is L24230GJ1995PLC025878 and registration number is 025878.
|Shares in Float||25.31|
|No of funds||258|
|U/D Vol ratio||1|
|LTDebt / Equity||28|
|Foreign Portfolio Investors||3.42%||2.52%||2.61%||2.86%|
|Financial Institutions/ Banks||0.01%|
Zydus Lifesciences Management
|Mr. Pankaj R Patel||Chairman|
|Dr. Sharvil P Patel||Managing Director|
|Mr. Ganesh N Nayak||Executive Director|
|Mr. Bhadresh K Shah||Independent Director|
|Mr. Mukesh M Patel||Non Executive Director|
|Mr. Nitin R Desai||Independent Director|
|Ms. Dharmishtaben N Raval||Independent Woman Director|
|Ms. Apurva S Diwanji||Independent Director|
|Mr. Upasana Konidela||Ind. Non-Executive Director|
|Mr. Monappa Arun Akhil||Ind. Non-Executive Director|
Zydus Lifesciences Forecast
Zydus Lifesciences Corporate Action
|2023-05-18||Audited Results & Final Dividend|
|2022-05-20||Audited Results, Dividend & Buy Back|
|2023-07-28||FINAL||Rs.6.00 per share(600%)Final Dividend|
|2022-07-29||FINAL||Rs.2.50 per share(250%)Final Dividend|
Zydus Lifesciences FAQs
What is Share Price of Zydus Lifesciences ?
Zydus Lifesciences share price is ₹510 As on 06 June, 2023 | 08:16
What is the Market Cap of Zydus Lifesciences ?
The Market Cap of Zydus Lifesciences is ₹51632.5 Cr As on 06 June, 2023 | 08:16
What is the P/E ratio of Zydus Lifesciences ?
The P/E ratio of Zydus Lifesciences is 26.3 As on 06 June, 2023 | 08:16
What is the PB ratio of Zydus Lifesciences ?
The PB ratio of Zydus Lifesciences is 2.6 As on 06 June, 2023 | 08:16
What were the company's most recent reported sales and net income?
Zydus Lifesciences Ltd. recorded a net income of INR 15,265.20 crores in FY22
What is the future of the company's shares?
Zydus Lifesciences Ltd. stock is a good option for long-term investment since the shares are ripe for buying right now.
How to buy shares of Zydus Lifesciences Ltd.?
The company's shares can be bought online or offline by opening a Demat account with 5Paisa and verifying the KYC documents.